What comes next for Nimbus after Takeda’s zasocitinib psoriasis acquisition?

Nimbus is using the Takeda zasocitinib deal as a reference point, but the bigger story is whether its AI-enabled discovery approach can repeatedly generate viable drug candidates. The article says investors and pharma partners now care less about one $4B psoriasis asset and more about durable pipeline productivity.